303 related articles for article (PubMed ID: 31959413)
21. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Brufsky A; Kennedy L; Bhatta S; Bhowmik D; Buchanan J; Despiegel N; Hechmati G
J Med Econ; 2020 Jan; 23(1):37-47. PubMed ID: 31364885
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity.
Wang BC; Wong ES; Alfonso-Cristancho R; He H; Flum DR; Arterburn DE; Garrison LP; Sullivan SD
Eur J Health Econ; 2014 Apr; 15(3):253-63. PubMed ID: 23526126
[TBL] [Abstract][Full Text] [Related]
23. Diverse approaches to the health economic evaluation of bariatric surgery: a comprehensive systematic review.
Campbell JA; Venn A; Neil A; Hensher M; Sharman M; Palmer AJ
Obes Rev; 2016 Sep; 17(9):850-94. PubMed ID: 27383557
[TBL] [Abstract][Full Text] [Related]
24. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
[TBL] [Abstract][Full Text] [Related]
25. Bariatric Surgery Prior to Total Hip Arthroplasty Is Cost-Effective in Morbidly Obese Patients.
Premkumar A; Lebrun DG; Sidharthan S; Penny CL; Dodwell ER; McLawhorn AS; Nwachukwu BU
J Arthroplasty; 2020 Jul; 35(7):1766-1775.e3. PubMed ID: 32278487
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity.
Alsumali A; Eguale T; Bairdain S; Samnaliev M
Obes Surg; 2018 Aug; 28(8):2203-2214. PubMed ID: 29335933
[TBL] [Abstract][Full Text] [Related]
27. The real-world cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost-utility analysis.
Lester ELW; Padwal RS; Birch DW; Sharma AM; So H; Ye F; Klarenbach SW
CMAJ Open; 2021; 9(2):E673-E679. PubMed ID: 34145050
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Klebanoff MJ; Corey KE; Samur S; Choi JG; Kaplan LM; Chhatwal J; Hur C
JAMA Netw Open; 2019 Feb; 2(2):e190047. PubMed ID: 30794300
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of nonoperative management versus open and laparoscopic surgery for uncomplicated acute appendicitis in Colombia.
Guevara-Cuellar CA; Rengifo-Mosquera MP; Parody-Rúa E
Cost Eff Resour Alloc; 2021 Jun; 19(1):34. PubMed ID: 34112179
[TBL] [Abstract][Full Text] [Related]
30. Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity.
Mital S; Nguyen HV
Am J Gastroenterol; 2019 Sep; 114(9):1470-1477. PubMed ID: 31490227
[TBL] [Abstract][Full Text] [Related]
31. Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight.
Ademi Z; Tomonaga Y; van Stiphout J; Glinz D; Gloy V; Raatz H; Bucher HC; Schwenkglenks M
Swiss Med Wkly; 2018; 148():w14626. PubMed ID: 29894556
[TBL] [Abstract][Full Text] [Related]
32. The Alberta population-based prospective evaluation of the quality of life outcomes and economic impact of bariatric surgery (APPLES) study: background, design and rationale.
Padwal RS; Majumdar SR; Klarenbach S; Birch DW; Karmali S; McCargar L; Fassbender K; Sharma AM
BMC Health Serv Res; 2010 Oct; 10():284. PubMed ID: 20932316
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.
Wentworth JM; Dalziel KM; O'Brien PE; Burton P; Shaba F; Clarke PM; Laiteerapong N; Brown WA
J Diabetes Complications; 2017 Jul; 31(7):1139-1144. PubMed ID: 28462893
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of bariatric and metabolic surgery, and implications of COVID-19 in the United Kingdom.
Galvain T; Patel S; Kabiri M; Tien S; Casali G; Pournaras DJ
Surg Obes Relat Dis; 2021 Nov; 17(11):1897-1904. PubMed ID: 34452846
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.
Pollock RF; Muduma G; Valentine WJ
Diabetes Obes Metab; 2013 Feb; 15(2):121-9. PubMed ID: 22882321
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes.
Hoerger TJ; Zhang P; Segel JE; Kahn HS; Barker LE; Couper S
Diabetes Care; 2010 Sep; 33(9):1933-9. PubMed ID: 20805271
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
38. Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome.
Neff R; Havrilesky LJ; Chino J; O'Malley DM; Cohn DE
Gynecol Oncol; 2015 Sep; 138(3):597-602. PubMed ID: 26232518
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis for bariatric surgery compared with usual care for the treatment of obesity in Australia.
James R; Salton RI; Byrnes JM; Scuffham PA
Surg Obes Relat Dis; 2017 Dec; 13(12):2012-2020. PubMed ID: 28237564
[TBL] [Abstract][Full Text] [Related]
40. Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy.
Rognoni C; Falivena C; Costa F; Armeni P
Pharmacoeconomics; 2023 Feb; 41(2):209-225. PubMed ID: 36662417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
